| abstract |
REFERS TO A COMPOUND OF FORMULA I, WHERE R1 AND R2 ARE EACH H, HYDROXYL, HALOGEN, OPTIONALLY SUBSTITUTED C1-C10 ALKYL, C1-C10 ALKYLTIOL, AMONG OTHERS; R3 AND R4 ARE EACH H, HYDROXYL, HALOGEN, CYANE, C1-C5 PERFLUOROALKYL, AMONG OTHERS; R5 IS C1-C10 ALKYL, SUBSTITUTED OR NOT, OPTIONALLY SUBSTITUTED C3-C7 CYCLOALKYL, SUBSTITUTED ARYL, AMONG OTHERS; R6 IS C1-C5 ALKYL, C3-C7 CYCLOALKYL, (C3-C7 CYCLOALKYL) - (C1-C8 ALKYL), AMONG OTHERS; R7 IS HALOGEN, C1-C10 ALKYL SUBSTITUTED OR NOT, AMONG OTHERS; R8 AND R9 TOGETHER REPRESENT A CARBO OR HETERO CYCLE RING GROUP OF 5-8 MEMBERS, SATURATED OR NOT, SUBSTITUTED WITH 1-2 CETO GROUPS, 1-2 C1-C5 ALKYL GROUPS, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: 2-FLUORO-5 - [(8-FLUORO-2-METHYLQUINAZOLIN-5-IL) AMINO] -5,6,7,8-TETRAHYDRO-7,8-DIMETHYL-8- (TRIFLUORomethyl) NAFTALIN- 1,6-DIOL; 2-FLUORO-5 - [(7-FLUORO-2-METHYLQUINAZOL-5-IL) AMINO] -5,6,7,8-TETRAHYDRO-7,8-DIMETHYL-6- (TRIFLUOROMETHYL) NAPHTHALIN-1,6- DIOL; 6-CHLORO-5-METOXY-1 - [(2-METHYLQUINAZOLINE-5-IL) AMINO] -3-METHYL-4-METHYLENE-2- (TRIFLUOROMETHYL) -1,2,3,4-TETRAHYDRONAPHTHALIN-2-OL ; AMONG OTHERS. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE INHIBITORS OF INFLAMMATION |